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Abstract
Background: The genetic basis of haemorrhagic stroke has proved difficult to unravel, partly hampered by the small
numbers of subjects in any single study. A meta-analysis of all candidate gene association studies of haemorrhagic stroke
(including ruptured subarachnoid haemorrhage and amyloid angiopathy-related haemorrhage) was performed, allowing
more reliable estimates of risk.
Methods: A systematic review and meta-analysis of all genetic studies in haemorrhagic stroke was conducted. Electronic
databases were searched until and including March 2007 for any candidate gene in haemorrhagic stroke. Odds ratio (OR)
and 95% confidence intervals (CI) were determined for each gene disease association using fixed and random effect models.
Results: Our meta-analyses included 6,359 cases and 13,805 controls derived from 55 case-control studies, which included
12 genes (13 polymorphisms). Statistically significant associations with haemorrhagic stroke were identified for those
homozygous for the ACE/I allele (OR, 1.48; 95% CI, 1.20–1.83; p=0.0003) and for the 5G allele in the SERPINE1 4G/5G
polymorphism (OR, 1.42; 95% CI, 1.03–1.96; p=0.03). In addition, both E2 and E4 alleles of APOE were significantly
associated with lobar haemorrhage (OR, 1.81; 95% CI, 1.26–2.62; p=0.002 and OR, 1.49; 95% 1.08–2.05; p=0.01 respectively).
Furthermore, a significant protective association against haemorrhagic stroke was found for the factor V Leiden mutation
(OR, 0.30; 95% CI, 0.10–0.87; p=0.03).
Conclusion: Our data suggests a genetic contribution to some types of haemorrhagic stroke, with no overall responsible
single gene but rather supporting a polygenic aetiology . However, the evidence base is smaller compared to ischaemic
stroke. Importantly, for several alleles previously found to be associated with protection from ischaemic stroke, there was a
trend towards an increased risk of haemorrhagic stroke.
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Introduction
Haemorrhagic stroke accounts for approximately 13% of all
stroke and is associated with a mortality rate four times higher
than ischaemic stroke,[1,2] with only 38% of haemorrhagic stroke
patients surviving beyond the first year.[3] Intracranial haemor-
rhage can be subdivided into extradural, subdural, subarachnoid,
intraventricular and intracerebral (with/without subarachnoid
and/or intraventricular) haemorrhage. Primary intracerebral
haemorrhage (ICH) originates from the spontaneous rupture of
small vessels damaged by chronic hypertension or cerebral
amyloid angiopathy,[4] while secondary intracerebral haemor-
rhage is most commonly associated with subarachnoid haemor-
rhage (SAH)_due to ruptured intracranial aneurysms or ruptured
arteriovenous malformations. Haemorrhage from rupture of
hypervascular tumors or impaired coagulation occurs in a very
small proportion of cases while traumatic related haemorrhage
tends to have different characteristics.
Although significant progress has been made towards unravel-
ing the basis of single gene stroke disorders and common
ischaemic stroke [5,6], identifying the underlying genes for
multifactorial haemorrhagic stroke for which there is no obvious
Mendelian pattern of inheritance, has proved difficult. This is
despite the evidence for a genetic contribution towards haemor-
rhagic stroke being considerable (with a likely greater genetic effect
for SAH compared to ICH). Stroke cases have also been found to
cluster in families. Approximately 10% of patients with intrace-
rebral haemorrhage have a positive family history of haemorrhagic
stroke [7], and having a first-degree relative with intracerebral
haemorrhage has been found to be a risk factor for developing the
disease. First degree relatives of patients with subarachnoid
haemorrhage have up to a seven-fold increased risk of subarach-
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10% of patients with aneurysmal subarachnoid haemorrhage have
a first or second degree relative with subarachnoid haemorrhage
or unruptured intracranial aneurysm.[10,11]
Genetic association studies in haemorrhagic stroke have
identified a considerable number of candidate genes, however,
due to lack of reproducibility, uncertainty remains about the
nature and number of genes contributing to risk of haemorrhagic
stroke.[6] There is concern, on one hand, that positive associations
might be spurious and, on the other hand, that the negative
findings from some studies might be a consequence of inadequate
statistical power from small sample size or methodological
shortcomings, such as selection of inappropriate control
groups.[12,13] The use of a genetic meta-analysis strategy
overcomes some of these limitations, although the results are
limited by the available data. Therefore, in this study a
comprehensive literature-based meta-analysis of all published
association studies in mainly primary intracerebral and aneurys-
mal subarachnoid forms of haemorrhage was undertaken.
Methods
Data sources
Electronic searches initially using PubMed, Embase and Google
Scholar were used to identify published genetic association studies
evaluating any candidate gene and any form of haemorrhagic
stroke in humans published until and including March 2007.
Letters and abstracts were included in the searches.
The Medical Subject Headings and text words used for the
search were: haemorrhagic stroke, intracerebral haemorrhage, intracranial
haemorrhage, subarachnoid haemorrhage, intracranial aneurysm, aneurysmal
h(a)emorrhage, arteriovenous malformation, cerebrovascular malformation,
cavernous angioma and cerebral amyloid angiopathy in combination with
polymorphism, gene, genotype or mutation. Search results were limited to
‘human’. All languages were searched and translated when
necessary. The references of all identified publications were
searched for additional studies and the MEDLINE option related
articles was used to examine all relevant articles.
Study selection
Selection criteria included case-control or cohort studies where
stroke was analyzed as a dichotomous trait. Studies were selected if
neuroimaging (magnetic resonance imaging, computerised tomog-
raphy or angiography) or autopsy had been used to confirm a
diagnosis of intracerebral haemorrhage, subarachnoid haemor-
rhage, ruptured intracranial aneurysm or cerebral amyloid
angiopathy-related haemorrhage. Control populations: The vast
majority of the time subjects classified as ‘controls’ had not been
subjected to neuro-imaging with investigators assuming that any
haemorrhage would be clinically detectable. Different sub-types of
haemorrhages were combined on the basis that its aetiology, in the
broadest sense, is vessel damage. Moreover, most investigators in
our study combined such data. However, haemorrhagic sub-type
data was analyzed separately where possible, e.g. Factor V Leiden.
Studies of all ethnic backgrounds were included. Genes with three
or more publications on each SNP were included in our analyses
but, if very large numbers of subjects were identified in only two
studies dealing with a solitary SNP these were included. Studies
were excluded if (1) the patients were children (aged ,18 years), (2)
genotype frequency was not adequately reported (and such data
could not be obtained from the authors), (3) genotype frequency of
haemorrhagic stroke sub-types were not reported independently
from ischaemic stroke cases, (4) cases due to trauma, haemorrhagic
rupture of tumour or haemorrhagic conversion of ischaemic stroke
were included in case genotype frequencies, or (5) quantitative
traits or intermediate phenotypes were investigated. Data from
SNP investigated in three or more studies are presented.
Data extraction
The first pass data extraction was undertaken by GP. Several
subsequent passes were then undertaken by GP and PS to ensure
comprehensive inclusion of appropriate studies. Once studies were
identified data was extracted initially by GP and then checked by
PS. For studies with more than one publication describing results
among the same or overlapping groups of patients or controls the
largest of the available published data sets was included to avoid
double counting. For studies with more than one control group,
the most appropriate control group was used. Where neither
control group was methodologically superior the largest was used.
Statistical analysis
Data wereanalyzedusingsoftwareforpreparingand maintaining
Cochrane reviews (Review Manager v4.2.8, Cochrane Collabora-
tion, http://www.cc-ims.net/RevMan) and Comprehensive Meta
Analysis v2.2.023 (Biostat, http://www.biostat.org). To determine
the strength of genetic association a pooled odds ratio (OR) was
calculated for each gene variant using fixed- and random-effects
models, in addition to the calculation of 95% confidence intervals
(CI). Fixed-effects summary ORs were calculated using the Mantel-
Haenszel method,[14,15] and the DerSimonian and Laird method
was used to calculate random-effects summary ORs [16]. The
results were very similar for both summary OR so only one is
presented. The frequency of at-risk genotypes was compared
between casesandcontrols for eachsinglenucleotide polymorphism
(SNP) analyzed. For each meta-analysis, the I
2 was calculated and a
chi-squared test for heterogeneity was performed.[17] The genetic
models used reflected those evaluated in the primary publication.
For assessment of small-study bias, funnel plots and the Egger
regression asymmetry test were conducted for each SNP with four
or more publications.[18]
The proportion of haemorrhagic stroke cases in the population
that could be attributed to a particular gene variant (population-
attributable risk [PAR]) was estimated as follows:
PAR~100| Prevalence| OR{1 ðÞ =Prevalence| OR{1 ðÞ z1 ½ 
For this calculation the fixed effects model was used and the
prevalence of exposure was estimated as the genotype frequency
among control adults.
Results
Our initial search identified 1,565 studies of which 85 met our
inclusion criteria. In total, 40 polymorphisms in 27 genes were
identified. Genes with three or more publications on each SNP
were included in our analyses, leaving a total of 55 publications
addressing 13 polymorphisms in 12 genes (Figure 1).
From the 12 genes analysed in detail (representing 6,367 cases
and 13,504 controls), the mean number of studies per candidate
gene was five. Six (46%) of the 13 meta-analyses had more than
500 cases, and 8 (62%) had a total participant size of greater than
1000 (Table 1). No single meta-analysis had more than 2000 cases.
Table 2 shows the genotypic odds ratios (ORs) for the 13
polymorphisms evaluated.
Apolipoprotein E:
The most investigated gene was apolipoprotein E, with 11
studies [19–29] that included 1376 cases and 3531 controls. APOE
Genetics, Haemorrhagic Stroke
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E2E4+E3E4+E4E4 vs all other genotypes or E2E2+E2E3+E2E4 vs all
other genotypes). For intracerebral haemorrhage, no association
was found for carriers of the E2 allele (Figure 2a) (OR, 1.09; 95%
CI, 0.88–1.35), but an association was observed for carriers of the
E4 allele (Figure 2b) with an OR of 1.17 (95% CI, 0.98–1.40;
P=0.08). No significant interstudy OR heterogeneity was
observed for either allele (x
2=9.54; PHet=0.30 and x
2=7.48;
PHet=0.49 respectively).
For subarachnoid haemorrhage, no association was found for
carriers of the E2 (Figure 2c) or E4 (Figure 2d) allele with ORs of
1.20 (95% CI, 0.85–1.70; p=0.30) and 1.22 (95% CI, 0.90–1.64;
p=0.19), respectively. No significant interstudy OR heterogeneity
was observed for either allele.
Only two publications (64 cases and 430 controls) with genotype
frequencies addressed cerebral amyloid angiopathy-related haem-
orrhage. McCarron et al. [23] used histology to confirm a diagnosis
of CAAH, while Garcia et al. [25] used neuroimaging and clinical
criteria to diagnose ‘probable/possible’ CAAH. Carriers of the E2
allele demonstrated an OR of 3.36 (95% CI, 1.71–6.59; p=0.0004)
(Figure 2e) and for carriers of E4 an OR of 2.69 (95% CI, 1.47–4.92;
p=0.001) (Figure 2f) for this condition. No significant interstudy
Figure 1. Flow chart illustrating number of studies included in the meta-analyses.
doi:10.1371/journal.pone.0003691.g001
Table 1. Details of size of studies included in each gene investigated.
Gene Polymorphism
No. of
studies
No. of
cases
No. of
controls
Average no. of
cases/study
Largest study
(cases/controls)
Smallest study
(cases/controls)
Apolipoprotein E e2, e3, e4 11 1276 3531 125 333/634 48/24
ACE I/D 8 744 1289 93 258/299 38/38
SERPINA3 A/T 6 1069 1294 178 437/405 38/80
SERPINE1 4G/5G 5 240 1233 48 60/485 31/60
Factor XIII Val/Leu 5 531 1172 106 201/201 64/127
MTHFR C677T 5 635 2275 127 503/1832 20/24
eNOS T-786C 4 893 784 223 411/405 52/90
Factor V Leiden R/Q 506 G/A 3 285 836 98 201/201 38/247
Endoglin Exon7/8 G/A insertion 3 285 512 95 119/119 63/191
Glycoprotein 1b-a VNTR repeat BCD 3 301 666 100 141/141 57/422
Glycoprotein Ia Glu505Lys and C807T 3 286 590 95 141/141 42/346
Glycoprotein IIIa Leu33Pro 3 286 590 95 141/141 42/346
doi:10.1371/journal.pone.0003691.t001
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2=0.78;
PHet=0.36 and E4: x
2=0.55; PHet=0.45).
Previous studies investigating apolipoprotein E in haemorrhagic
stroke have addressed the association of the E2 and E4 alleles in
lobar and non-lobar haemorrhage.[30] Four studies [20,22,23,25]
provided data that appropriately categorized haemorrhage
location as lobar or non-lobar. Both E2 and E4 alleles were
significantly associated with lobar haemorrhage (OR, 1.81; 95%
CI, 1.26–2.62; P=0.002 and OR, 1.49; 95% 1.08–2.05; P=0.01
respectively) but not with non-lobar haemorrhage (OR, 1.08; 95%
CI, 0.80–1.47 and OR, 1.05; 95% CI, 0.81–1.37) (Figures 2g and
2h). No significant interstudy OR heterogeneity was observed for
Table 2. Summary data of candidate genes in haemorrhagic stroke.
Gene Polymorphism
Genetic
model
Stroke
subtype
Number
of
studies Cases Controls OR (95% CI)
Phet
value
Frequency
of at risk
allele No.
Frequency
of at risk
allele No.
Apolipoprotein E e2, e3, e4 Dominant All HS 11 0.174 1376 0.125 3531 1.17 (0.98, 1.41) 0.41
ICH 9 0.072 929 0.053 3186 1.09 (0.88, 1.35) 0.30
SAH 4 0.091 383 0.058 1877 1.20 (0.85, 1.70) 0.90
CAAH 2 0.180 64 0.078 430 3.36 (1.71, 6.59) 0.38
Lobar 4 - 244 - 393 1.81 (1.26, 2.62) 0.07
Non-lobar 4 - 437 - 1115 1.08 (0.80, 1.47) 0.57
e2, e3, e4 Dominant All HS 11 0.257 1376 0.231 3531 1.18 (1.01, 1.37) 0.36
ICH 9 0.128 929 0.116 3186 1.17 (0.98, 1.40) 0.49
SAH 4 0.120 383 0.112 1877 1.22 (0.90, 1.64) 0.15
CAAH 2 0.180 64 0.176 430 2.69 (1.47, 4.92) 0.46
Lobar 4 - 244 - 939 1.49 (1.08, 2.05) 0.36
Non-lobar 4 - 437 - 1115 1.05 (0.81, 1.37) 0.41
SERPINE1 4G/5G Recessive All HS 5 0.490 240 0.443 1446 1.42 (1.03, 1.96) 0.99
ICH 4 0.490 198 0.443 1102 1.40 (0.98, 2.00) 0.97
ACE I/D Recessive All HS 8 0.487 744 0.544 1289 0.92 (0.75, 1.14) 0.12
ICH 5 0.523 280 0.558 719 1.00 (0.73, 1.36) 0.11
SAH 3 0.464 464 0.526 570 0.87 (0.65, 1.14) 0.49
I/D Recessive All HS 8 0.513 744 0.456 1289 1.48 (1.20, 1.83) 0.02
ICH 5 0.477 280 0.442 719 1.27 (0.90, 1.77) 0.20
SAH 3 0.536 464 0.474 570 1.64 (1.24, 2.17) 0.009
Factor V Leiden R/Q 506 G/A Dominant All HS 3 0.007 285 0.024 836 0.31 (0.11, 0.90) 0.69
ICH 3 0.005 190 0.024 836 0.29 (0.08, 1.05) 0.50
SAH 2 0.011 95 0.022 589 0.45 (0.11, 1.95) 0.61
Endoglin Exon7/8 G/A insertion Recessive All HS 3 0.170 285 0.183 512 3.47 (1.45, 8.30) 0.56
SERPINA3 A/T Recessive All HS 6 0.493 1069 0.481 1294 1.10 (0.91, 1.33) 0.40
ICH 4 0.553 452 0.431 626 1.28 (0.98, 1.67) 0.47
SAH 2 0.450 616 0.453 668 0.94 (0.71, 1.24) 0.64
eNOS T-786C Dominant SAH 4 0.127 893 0.133 784 1.27 (0.99, 1.62) 0.62
MTHFR C677T Recessive ICH 5 0.449 635 0.42 2275 1.11 (0.89, 1.39) 0.12
Factor XIII Val/Leu Recessive All HS 5 0.266 531 0.26 1172 1.36 (0.89, 2.08) 0.11
Glycoprotein 1b-a VNTR repeat BCD Dominant All HS 3 0.075 301 0.041 666 1.04 (0.66, 1.64) 0.24
Glycoprotein Ia Glu505Lys Dominant All HS 3 0.101 286 0.107 590 0.82 (0.56, 1.20) 0.36
C807T Dominant All HS 3 0.386 286 0.369 590 1.15 (0.83, 1.59) 0.79
Glycoprotein IIIa Leu33Pro Dominant All HS 3 0.133 286 0.164 590 0.76 (0.54, 1.07) 0.12
Apo e2 (bold) vs others.
Apo e4 (bold) vs others.
Abbreviations: OR, fixed effect odds ratio; P Het, P value for heterogeneity; ACE, gene encoding angiotensin converting enzyme; eNOS, gene encoding endothelial nitric
oxide synthase; MTHFR, gene encoding methylenetetrahydrofolate reductase; I/D, insertion/deletion; VNTR, variable number tandem repeat; All HS, all haemorrhagic
stroke; ICH, intracerebral haemorrhage; SAH, subarachnoid haemorrhage; CAAH, cerebral amyloid angiopathy-related haemorrhage.
Table shows both alleles with the one used for analysis in bold followed by the genetic model used for genotype characterisation. Apo e2 (bold) vs others. Apo e4 (bold)
vs others.
doi:10.1371/journal.pone.0003691.t002
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2=6.91; PHet=0.07; E2 non-lobar:
x
2=2.01; PHet=0.57; E4 lobar: x
2=3.20; PHet=0.36; E4 non-
lobar: x
2=2.88; PHet=0.41).
SERPINE1:
A total of five studies [31–35] (240 cases and 1233controls)
investigated the SERPINE1 (also known as plasminogen activator
inhibitor-1) 4G/5G polymorphism. Four addressed intracerebral
haemorrhage and one study [33] addressed intracerebral haem-
orrhage, subarachnoid haemorrhage and ruptured intracranial
aneurysm. For intracerebral haemorrhage alone an association
was observed for those homozygous for the 5G allele with an OR
of 1.40 (95% CI, 0.98–2.00; P=0.07) (Figure 3). When
subarachnoid haemorrhage and ruptured intracranial aneurysm
Figure 2. 2a. Results for apolipoprotein E2 allele and intracerebral haemorrhage comparing carriers of the E2 allele with those with the E3 and E4
alleles. 2b. Results for apolipoprotein E4 allele and intracerebral haemorrhage comparing carriers of the E4 allele with those with the E2 and E3 alleles.
2c. Results for apolipoprotein E2 allele and subarachnoid haemorrhage comparing carriers of the E2 allele with those with the E3 and E4 alleles. 2d.
Results for apolipoprotein E4 allele and subarachnoid haemorrhage comparing carriers of the E4 allele with those with the E2 and E3 alleles. 2e.
Results for apolipoprotein E2 allele and cerebral amyloid angiopathy-related haemorrhage comparing carriers of the E2 allele with those with the E3
and E4 alleles. 2f. Results for apolipoprotein E4 allele and cerebral amyloid angiopathy-related haemorrhage comparing carriers of the E4 allele with
those with the E2 and E3 alleles. 2g. Results for apolipoprotein E2 allele and lobar or non-lobar haemorrhage comparing carriers of the E2 allele with
those with the E3 and E4 alleles. 2h. Results for apolipoprotein E4 allele and lobar or non-lobar haemorrhage comparing carriers of the E4 allele with
those with the E2 and E3 alleles.
doi:10.1371/journal.pone.0003691.g002
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observed with a similar OR of 1.42 (95% CI, 1.03–1.96; P=0.03).
No significant interstudy OR heterogeneity was observed
(x
2=0.28; PHet=0.99). The distribution of the OR in relation to
its standard deviation in the funnel plot was symmetrical, and the
Egger test result was not significant (P=0.178), suggesting a low
probability of small-study bias.
Angiotensin-Converting Enzyme:
A total of 8 studies [36–43] (744 cases and 1289 controls) were
identified that evaluated the ACE/ID polymorphism of which five
related to intracerebral haemorrhage, one for subarachnoid
haemorrhage and two for ruptured intracranial aneurysm.
No significant association for haemorrhagic stroke was found for
those homozygous for the D allele (ACE/DD) for intracerebral
haemorrhage alone (OR, 1.00; 95% CI, 0.73–1.36; p=1.00), or
with subarachnoid haemorrhage or ruptured intracranial aneu-
rysm (OR, 0.87; 95% CI, 0.65–1.14; p=0.09). In addition to
examining the association of the ACE/DD genotype with
haemorrhagic stroke, several studies have suggested that the
ACE/II genotype may be associated with haemorrhagic stroke.
When all studies were evaluated together, those homozygous for
the ACE/I allele demonstrated an overall pooled OR of 1.48 (95%
CI, 1.20–1.83; p=0.0003) (Figure 4). Significant interstudy OR
heterogeneity was observed (x
2=16.69; PHet=0.02), however a
random-effect model that takes into account the intra- and inter-
study variability resulted in a similar overall estimate that
remained significant (OR, 1.45; 95% CI, 1.01–2.07; p=0.04).
The distribution of the OR in relation to its standard deviation in
the funnel plot was symmetrical, and the Egger test result was not
significant (p=0.667), suggesting a low probability of small-study
bias. For intracerebral haemorrhage alone this association did not
remain significant (OR, 1.27; 95% CI, 0.90–1.77; P=0.17).
However, for subarachnoid haemorrhage or ruptured intracranial
aneurysm, a summary OR, under a fixed-effect model, of 1.64
(95% CI, 1.24–2.17; p=0.0003) was observed.
Factor V:
Three studies (285 cases, 836 controls) investigated haemor-
rhagic stroke in the factor V Leiden mutation. One addressed
intracerebral haemorrhage [44] and two addressed both intrace-
rebral haemorrhage and subarachnoid haemorrhage [45,46].
When considered in totality, carriers of the adenine allele were less
likely to develop haemorrhagic stroke (OR, 0.31; 95% CI, 0.11–
Figure 3. Results for SERPINE1 4G/5G and intracerebral haemorrhage of 5G allele homozygous (5G/5G) genotype.
doi:10.1371/journal.pone.0003691.g003
Figure 4. Results for ACE/II gene and haemorrhagic stroke.
doi:10.1371/journal.pone.0003691.g004
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(Figure 5a). No significant interstudy heterogeneity was observed
(x
2=0.74; PHet=0.69)
For intracerebral haemorrhage alone, a summary OR, under
the fixed-effects model, of 0.29 (95% CI, 0.08–1.05; p=0.06) was
observed for adenine allele homozygotes (Figure 5b). For
subarachnoid haemorrhage alone, a summary OR, under a
fixed-effect model, of 0.45 (95% CI, 0.11–1.95; p=0.29) was
observed (Figure 5c). No significant interstudy heterogeneity was
observed for intracerebral (x
2=1.38; PHet=0.50) or subarachnoid
haemorrhage (x
2=0.26; PHet=0.61).
Endoglin:
Three studies (285 cases; 512 controls) investigated risk of
haemorrhagic stroke and the exon 7/8 GA insertion of the gene
encoding endoglin. One study addressed intracerebral haemor-
rhage [47] and two studies addressed subarachnoid haemorrhage
[48,49]. When considered in totality, those homozygous for the
insertion allele demonstrated an OR of 3.47 (95% CI, 1.45–8.30;
p=0.005). No significant interstudy OR heterogeneity was
observed (x
2=1.15; PHet=0.56).
SERPINA3:
A total of 6 studies [50–55] (1069 cases and 1294 controls) were
identified that evaluated the polymorphism in the gene encoding
SERPINA3 (also known as a1-antichymotrypsin) where alanine is
replaced by threonine. Four of these addressed intracerebral
haemorrhage and two addressed subarachnoid haemorrhage.
For intracerebral haemorrhage, a summary OR, under the
fixed-effects model, of 1.28 (95% CI, 0.98–1.67; p=0.07) was
observed for individuals homozygous for the T allele compared
with A allele carriers (AT+AA). For subarachnoid haemorrhage
alone, a summary OR, under a fixed-effect model, of 0.94 (95%
CI, 0.71–1.24; p=0.65) was observed (Figure 6). No significant
interstudy heterogeneity was observed (x
2=5.17; PHet=0.40) and
the funnel plot distribution was symmetrical with an insignificant
Egger test (P=0.14), indicating a low probability of small-study
bias.
Endothelial nitric oxide synthase:
The eNOS T786C mutation was evaluated in 4 studies [56–59],
all of which addressed subarachnoid haemorrhage with a total of
893 cases and 784 controls. The summary OR under a fixed-effect
model showed an OR for dominant carriers of the 786C mutation
of 1.27 (95% CI, 0.99–1.62; P=0.06) (Figure 7). No significant
interstudy heterogeneity was observed (x
2=1.76; PHet=0.62). The
distribution of the ORs from individual studies in relation to their
respective standard deviations was symmetrical, and the Egger test
result suggested a low probability of small-study bias (p=0.29).
Methylenetetrahydrofolate reductase:
Five studies [60–64] investigated the MTHFR C677T poly-
morphism, all addressing intracerebral haemorrhage (635 cases;
2275 controls). No significant association for intracerebral
haemorrhage was found for
677TT (OR, 1.11; 95% CI, 0.89–
1.39; p=0.35) (Figure 8). No significant interstudy heterogeneity
Figure 5. 5a. Results for Factor V Leiden mutation and haemorrhagic stroke. 5b. Results for Factor V Leiden mutation and ICH. 5c. Results for Factor
V Leiden mutation and SAH.
doi:10.1371/journal.pone.0003691.g005
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2=7.29; PHet=0.12) and the funnel plot
distribution was symmetrical with an insignificant Egger test
(p=0.27), indicating a low probability of small-study bias.
Factor XIII:
The factor XIII valine/leucine polymorphism was investigated
in 5 studies [33,65–68]. Subarachnoid haemorrhage was
addressed in addition to intracerebral haemorrhage in two of
these studies (531 cases; 1172 controls). When considered in
totality, those homozygous for the leucine allele demonstrated an
OR of 1.39 for haemorrhagic stroke (95% CI, 0.89–2.08),
although this result was not statistically significant (p=0.15). No
significant interstudy heterogeneity was observed (x
2=7.45;
PHet=0.11) and the funnel plot distribution was symmetrical with
an nonsignificant Egger test (p=0.27), indicating a low probability
of small-study bias. For intracerebral haemorrhage, a summary
OR under a fixed-effect model of 1.32 (95% CI, 0.82–2.06;
p=0.27) was observed for individuals homozygous for the leucine
allele compared with valine allele carriers (V/L plus V/V)).
Glycoprotein Ib-a:
Three studies investigated haemorrhagic stroke in the glycopro-
tein 1b-a VNTR polymorphism. Two addressed intracerebral
haemorrhage [69,70] (198 cases; 563 controls) and one addressed
subarachnoid haemorrhage [71] (103 cases; 103 controls). When
considered in totality carriers of the B group of tandem repeats had
no associated risk for haemorrhagic stroke with a summary OR,
under a fixed-effect model, of 1.04 (95% CI, 0.66–1.64; p=0.85).
Glycoprotein Ia and IIIa:
Three studies investigated haemorrhagic stroke in the glyco-
protein Ia Glu505Lys polymorphism [69,71,72] (286 cases; 590
controls). No association for haemorrhagic stroke was found for
carriers of the lysine allele with a summary OR, under the fixed-
effect model, of 0.82 (95% CI, 0.56–1.20). Additionally, the same
studies found no association for haemorrhagic stroke with the
C807T polymorphism of glycoprotein Ia (OR, 1.15; 95% CI,
0.83–1.59) nor for the glycoprotein IIIa Leu33Pro polymorphism
(OR, 0.76; 95% CI, 0.54–1.07).
Figure 6. Results for SERPINA3/TT in haemorrhagic stroke.
doi:10.1371/journal.pone.0003691.g006
Figure 7. Results for eNOS/786C polymorphism and subarachnoid haemorrhage.
doi:10.1371/journal.pone.0003691.g007
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In this comprehensive meta-analysis, four of the 13 (31%)
polymorphisms analyzed significantly increased the risk of
haemorrhagic stroke. The mean number of participants in two
of these meta-analyses (ACE and SERPINE1) was more than
1850, allowing more precise estimates to be made of the effect of
these genes than from any single study. The individual risk
provided by these candidate genes was moderate (OR, 1.48; 95%
CI: 1.20–1.83 and 1.42, 95% CI: 1.03–1.96, respectively). This
effect size is in broad agreement with previous studies in ischaemic
stroke [6] and other complex diseases that are thought to have a
polygenic basis, such as ischaemic heart disease [73,74]. Further,
our study suggests that the hypercoagulable state conferred by the
factor V Leiden mutation is protective against haemorrhagic
stroke (OR, 0.31; 95% CI, 0.11–0.90; p=0.03). This is in
accordance with previous studies that have suggested a protective
role for this polymorphism in other bleeding disorders. [75,76]
However, these results are based on a smaller dataset compared to
ischaemic stroke making the point estimates less reliable. The
seven gene variants in the six remaining genes – factor XIII,
MTHFR, SERPINA3 and glycoproteins Ia, 1b-a, and IIIa – have
so far failed to provide evidence to support an increased
susceptibility to haemorrhagic stroke.
The majority of candidate genes in haemorrhagic stroke have
been investigated initially for their potential role in ischaemic
stroke. For APOE, our results are in accordance with previous
histological studies suggesting that, while the E4 allele enhances the
deposition of amyloid-b in peripheral (lobar) cerebral vasculature,
the E2 allele predisposes to the rupture of these lobar amyloid-b
laden vessels, possibly through the promotion of fibrinoid necrosis
[77–79]
A meta-analysis of genetic studies in ischaemic stroke by our
group in 2004 investigated, among others, 9 (75%) of the 12
candidate genes in our study (Table 3) and involved approximately
3 times as many cases and controls. Although ischaemic and
haemorrhagic stroke may share some common risk factors they are
thought to have quite distinct molecular pathogeneses. Our
current work demonstrates strikingly similar genetic ORs between
the two major pathologies supporting a similar aetiological role for
both ischaemic and haemorrhagic stroke (Table 3) with a greater
patho-aetiological similarity existing between small vessel ischae-
mic disease and deep cerebral haemorrhage. Interestingly, Factor
V was associated with ischaemic stroke and protective for
haemorrhagic stroke, providing a biological relevant and impor-
tant role for its aetiology in cerebrovascular disease.
The population-attributable risks (PARs) for gene variants with
the most reliable associations for haemorrhagic stroke in this study
were 9.24% for the ACE/ID polymorphism and 7.78% for the
SERPINE1 4G/5G. These values are lower than those reported
for well-established risk factors for haemorrhagic stroke, such as
hypertension [80] but not surprising, because the genetic
contribution of any single gene toward a complex disease is
unlikely to act in a simple mendelian fashion but rather with
epistatic (gene-gene or gene-environmental interaction) effects.
Nevertheless, given the high incidence of haemorrhagic stroke
(100,000 per year in the United States), if these estimates hold true
they suggest that common variants in the ACE and SERPINE1
genes alone may contribute between 8,000–10,000 haemorrhagic
strokes in the United States each year.
The interpretation of any meta-analysis must be made within
the context of its limitations, including study selection, publication
bias, and variability in the methodological quality of the included
studies. A comprehensive search was undertaken for all relevant
studies including non-English language [19,55,81]. Although
publication bias can never be completely excluded, many of the
individual studies included in our meta-analyses were not
statistically significant and were interpreted by their authors as
negative studies suggesting a desire by authors to submit, and a
willingness by editors to publish such work. In addition, Egger
asymmetry tests and funnel plots showed no substantial evidence
of publication bias in the nine meta-analyses for which four or
more studies had been published (apolipoprotein E e4, and e2;
SERPINA3 A/T; eNOS T786C; ACE/ID; MTHFR C677T;
factor XIII Val/Leu and SERPINE1 4G/5G), although it is
acknowledged that at times the study numbers for each gene were
small as was the number of subjects for each study making the
point estimates less reliable when compared against our previous
larger meta-analyses in stroke [5,6]. Moreover, rigorous selection
criteria (use of neuroimaging or autopsy to diagnose haemorrhagic
stroke) enriched the meta-analyses for studies with comparable
selection of participants and haemorrhagic stroke sub-types.
Notwithstanding these selection criteria, patients with severe
ICH from any aetiology who died at onset without gaining access
to secondary care could not have entered in any of the included
manuscripts.
Only two of our meta-analyses included more than 1000 cases
(apolipoprotein E and SERPINA3). Reliable interpretation of the
association of candidate genes with haemorrhagic stroke will only
come from studies with an order of magnitude larger than those
performed to date. Dichgans et al.[82] suggest that to confirm
odds ratios between 1.2–1.5 in candidate genes with allele
frequencies between 0.1–0.5, sample sizes of 800–20,000 are
required to achieve reliable statistical significance at a P value of at
least 0.05. The average number of cases and controls in our meta-
analysis were just 578 and 1224 respectively. Achieving appropri-
Figure 8. Results for MTHFR/677TT gene and intracerebral haemorrhage.
doi:10.1371/journal.pone.0003691.g008
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collaborative approach, with studies using uniform criteria for the
selection of cases and controls and submitting both positive and
negative data to a common database for continuously updated and
cumulative meta-analysis. Using neuroimaging- or autopsy-
diagnosed haemorrhagic stroke as a selection criteria may have
helped to maintain comparable groups of cases. However the
selection of control groups varied considerably between studies
with some excluding control subjects with established hyperten-
sion, while others argued that as not all patients with haemor-
rhagic stroke have high blood pressure such exclusion of control
population is unnecessary. Statistical methods using marker
genotype data may in the future permit the detection and control
of confounding due to population stratification and selection bias
in genetic association studies.[83] This may reduce the impact of
variability within controls groups, although the strategy of using a
control group that has not been specifically phenotyped for
comparison with each individual disease has recently been
successfully employed [84] suggesting that this is not a major
problem.
All studies from different ancestral backgrounds were included.
Although there is evidence to suggest that allele frequencies for
several candidate genes investigated in our study vary between
ethnicity, and epidemiological studies suggest differences in the
incidence and prevalence of haemorrhagic stroke in certain ethnic
groups with the rate in black Americans twice that of white
Americans,[85,86] as well as a greater incidence in Japanese
population when compared to Caucasian populations [87], the
majority of our studies were conducted in Caucasians. Indeed, we
have recently shown in ischaemic stroke that differences in genetic
effects across different ethnic groups may be overstated [5].
However, the effect of heterogeneity by ethnicity cannot be
completely dismissed.
Only adults with ruptured intracranial aneurysm were included
in our analyses addressing subarachnoid haemorrhage. Many
published articles have investigated genetic polymorphisms in
subjects with unruptured intracranial aneurysm. While some genes
may predispose to the formation of intracranial aneurysms, others
may predispose to rupture of aneurysms. By performing a similar
meta-analysis of genetic association studies in unruptured
intracranial aneurysm it may be possible to further our
understanding of the genetic and molecular pathogenesis of
subarachnoid haemorrhage. Although attempts were made to
analyse sub-types of haemorrhage separately, the majority of the
time such data were not readily available. For this, as well as
reasons of aetiology where it can be argued that haemorrhagic
stroke at its most basic consists of vessel rupture, data were
combined. Readers should therefore assess this manuscript with
this limitation in mind. Further, even within the category of
primary intracerebral haemorrhage, heterogeneity may exist while
some patients may not have been subjected to detailed
investigations in order to determine secondary underlying causes,
thus erroneously labelling them clinically as ‘primary’.
Although it is not possible to exclude the future identification of
one or more genes with a more substantial effect on risk of
haemorrhagic stroke using different models such as genome wide
association searches, our findings based upon candidate gene
strategies suggest that several genes, each with a small to moderate
effect, are likely to act individually, together, or in combination with
environmental determinants to contribute towards haemorrhagic
stroke. One implication ofthese findingsisthat predictive genetic tests
that use any single variant are unlikely individually to have much
value. However, tests that combine genotyping for one or more risk
alleles and that integrate the results with established risk prediction
tools based on acquired risk factors may have greater utility.[88,89]
This study may have important implications for those involved in
exploring the genetic aetiology of blood pressure because of the
relationship between haemorrhagic stroke and hypertension. Few
studies (,50%) reported the prevalence of hypertension among
their case and control populations. Of those that did the average
incidenceof hypertension among cases intheACEstudy was51.7%
compared to 29.7% in controls, and for PAI-1 the average for cases
was 26.7% and for controls 12.9%. From our study the mechanism
by which causative SNPs lead to haemorrhagic stroke cannot be
certain, although this could be via known causal pathways such as
hypertension especially if those genes are involved in blood pressure
regulation. There is, therefore, a clear need for future investigators
andeditorstoensurethatthisimportantvariableisdocumented and
published in the final manuscripts.
In summary, this study suggests the existence of a genetic basis
for some types of haemorrhagic stroke with no single gene but
rather demonstrates a polygenic aetiology. However, the evidence
base is smaller than when compared against ischaemic stroke,
although the odds ratios are of similar magnitude. An international
collaborative approach is more likely to lead to a sufficient number
of subjects being recruited for the reliable identification of risk
alleles in haemorrhagic stroke.
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Table 3. Odds ratios and 95% CIs of gene variants investigated in both ischaemic and haemorrhagic stroke. Data taken from Casas
et al.
104 and Ariyaratnam et al.
97
Gene ACE ACE Factor V PAI-1 MTHFR APOE APOE
Polymorphism I/D I/D Arg506Gln 4G/5G C677T e2/e3/e4 e2/e3/e4
Stroke Subtype
Caucasian Ischaemic stroke 1.21 (1.08–1.35) - 1.33 (1.12–1.58) 1.47 (1.13–1.92) 1.24 (1.08–1.42) - 0.96 (0.84–1.11)
Non-European Ischaemic Stroke 1.82 (1.28–2.60) - - - 1.22 (0.98–1.52) - 1.77 (1.30–2.39)
Haemorrhagic stroke 0.92 (0.75, 1.14) 1.48 (1.20, 1.83) 0.30 (0.10, 0.87) 1.42 (1.03–1.96) 1.11 (0.89, 1.39) 1.17 (0.98–1.41) 1.18 (1.01–1.37)
Intracerebral haemorrhage 1.00 (0.73–1.36) 1.27 (0.90–1.77) - 1.40 (0.98–2.00) 1.11 (0.89, 1.39) 1.09 (0.88–1.35) 1.17 (0.98–1.40)
Subarachnoid haemorrhage 0.87 (0.65–1.14) 1.64 (1.24–2.17) - - - 1.20 (0.85–1.70) 1.22 (0.90–1.64)
Cerebral amyloid angiopathy -----3 . 3 6 (1.71–6.59) 2.69 (1.47–4.92)
doi:10.1371/journal.pone.0003691.t003
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